Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:4City/State/Province:Toyohashi, Aichi
Treatments:Chemotherapy, Biologic therapyHospital:Toyohashi Municipal Hospital
Drugs:Journal:Link
Date:Jan 2009

Description:

Patients: This phase 2 study involved forty-four patients with stage IIIB or IV non-small cell lung cancer. The majority (31) were men. The median age was 64, ranging from 34 to 75 years of age.

Treatment: Patients were treated with the chemotherapy drugs carboplatin and paclitaxel and the biological therapy meloxicam. Meloxicam is a selective COX-2 inhibitor.

Toxicity: Grade 4 neutropenia and gastrointestinal tract perforation were reported, in three and one patients, respectively. Grade 3 toxicities were leucopenia, neutropenia, thrombocytopenia, anemia and nausea.

Results: The median overall survival was 15.9 months.

Correspondence: Dr. Ryujiro Suzuki





Back